Abemaciclib

Drug Profile

Abemaciclib

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; CDK 4/6 dual inhibitor - Eli Lilly; Cyclin dependent kinase 4/6 dual inhibitor - Eli Lilly; Cyclin-dependent-kinase-inhibitors-Eli-Lilly; LY-2835219

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Emory University; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin D1 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer
  • Phase II Cancer; Liposarcoma; Mantle-cell lymphoma; Pancreatic cancer
  • Preclinical Solid tumours
  • Phase Unknown Glioblastoma

Most Recent Events

  • 11 Jan 2017 Eli Lilly initiates enrolment in a phase I trial for Cancer (Combination therapy) in USA
  • 01 Jan 2017 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in USA, Australia, Brazil, Taiwan (PO)
  • 01 Jan 2017 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Australia, Brazil, Taiwan (PO) (NCT02981342)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top